Literature DB >> 10491659

Hereditary endocrinopathies.

J F Moley1, T C Lairmore, J E Phay.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10491659     DOI： 10.1016/s0011-3840(99)80001-x

Source DB:  PubMed          Journal:  Curr Probl Surg        ISSN： 0011-3840            Impact factor:   1.909


× No keyword cloud information.
  7 in total

1.  Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.

Authors:  Mackenzie R Cook; Jie Luo; Mary Ndiaye; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Am J Surg       Date:  2010-03       Impact factor: 2.565

2.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

3.  Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival.

Authors:  Kevin Shepet; Amal Alhefdhi; Ngan Lai; Haggi Mazeh; Rebecca Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2012-11-29       Impact factor: 5.344

4.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

5.  Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report.

Authors:  D Pach; A Sowa-Staszczak; A Jabrocka-Hybel; A Stefańska; M Tomaszuk; R Mikołajczak; B Janota; M Trofimiuk-Müldner; E Przybylik-Mazurek; A Hubalewska-Dydejczyk
Journal:  Int J Endocrinol       Date:  2013-03-31       Impact factor: 3.257

6.  Medullary thyroid carcinoma.

Authors:  Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2003-08

7.  From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.

Authors:  Dariusz Pawlak; Christine Rangger; Petra Kolenc Peitl; Piotr Garnuszek; Michał Maurin; Laura Ihli; Marko Kroselj; Theodosia Maina; Helmut Maecke; Paola Erba; Leopold Kremser; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Clemens Decristoforo
Journal:  Eur J Pharm Sci       Date:  2016-01-27       Impact factor: 4.384
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.